T2 Biosystems, Inc. (TTOO)
TTOO Stock Price Chart
Key Info
| Market Cap | 176.07M |
| Revenue (ttm) | 13.41M |
| Net Income (ttm) | -50.93M |
| Shares Out | 147.79M |
| EPS (ttm) | -0.53 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | December 3 |
| Last Price | $1.19 |
| Previous Close | $1.15 |
| Change ($) | 0.04 |
| Change (%) | 3.48% |
| Day's Open | 1.16 |
| Day's Range | 1.14 - 1.21 |
| Day's Volume | 3,070,515 |
| 52-Week Range | 0.28 - 2.10 |
TTOO Stock News
Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 817 active prominent money managers and anal...
A struggling diagnostics platform is benefiting from Sars-COVID-2 tailwinds. Its sars-COVID-2 test is accelerating the uptake of its diagnostic platform.
LEXINGTON, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that the Company plans to pa...
T2 Biosystems, Inc. (TTOO) CEO John Sperzel on Q3 2020 Results - Earnings Call Transcript
T2 Biosystems (TTOO) delivered earnings and revenue surprises of 20.00% and 32.45%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of T2 Biosystems (NASDAQ:TTOO) fell 10% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share increased 74.19% over the past year to ($0.08...
Total revenues increase by 213% on record high quarterly product sales Total revenues increase by 213% on record high quarterly product sales
T2 Biosystems (TTOO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
John Sperzel will serve on the Industry Council of the Advisory Board John Sperzel will serve on the Industry Council of the Advisory Board
LEXINGTON, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced today that it will report financia...
Is (TTOO) Outperforming Other Medical Stocks This Year?
Advances Development of Diagnostics for Sepsis-Causing Pathogens, Antibiotic Resistance, and Biothreat Pathogens Advances Development of Diagnostics for Sepsis-Causing Pathogens, Antibiotic Re...
Is (TTOO) Outperforming Other Medical Stocks This Year?
Summit will raise awareness and highlight the critical role of rapid diagnostics for bloodstream infections, sepsis and the COVID-19 virus Summit will raise awareness and highlight the critica...
Payment Covers 65 Percent of the Average Cost of the Test Panel for Eligible Patients Payment Covers 65 Percent of the Average Cost of the Test Panel for Eligible Patients
The T2SARS-CoV-2™ Panel runs on the FDA-cleared T2Dx® Instrument The T2SARS-CoV-2™ Panel runs on the FDA-cleared T2Dx® Instrument
Convalescent plasma stocks moved northward following FDA's emergency plasma authorization for COVID-19 treatment. Here're three of them that should be on your watch list -
Health care stocks levered to blood collection and sampling, and plasma therapy biopharma companies are getting a big boost Monday after the FDA issued emergency use authorization for the use ...
Investors need to pay close attention to T2 Biosystems (TTOO) stock based on the movements in the options market lately.
T2 Biosystems, Inc. (TTOO) CEO John Sperzel on Q2 2020 Results - Earnings Call Transcript
Shares of T2 Biosystems (NASDAQ: TTOO) decreased 7.49% in after-market trading after the company reported Q2 results.
LEXINGTON, Mass., Aug. 11, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced financial results for the ...
T2 Biosystems (NASDAQ: TTOO) announces its next round of earnings this Tuesday, August 11.
LEXINGTON, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced today that its Board of Director...
In the latest trading session, T2 Biosystems (TTOO) closed at $1.66, marking a +1.84% move from the previous day.
LEXINGTON, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that the Company plans to ...
LEXINGTON, Mass., July 28, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced today that it will report financ...
T2 Biosystems' (TTOO) second-quarter results are likely to reflect growth in product revenues.
In the latest trading session, T2 Biosystems (TTOO) closed at $1.62, marking a +0.62% move from the previous day.
In the latest trading session, T2 Biosystems (TTOO) closed at $1.33, marking a -0.75% move from the previous day.
T2 Biosystems Inc. (NASDAQ: TTOO) solidified its position as a coronavirus stock on Wednesday morning when it announced the launch of its COVID-19 molecular diagnostic test.
The T2SARS-CoV-2™ Panel will run on the FDA cleared T2Dx® Instrument The T2SARS-CoV-2™ Panel will run on the FDA cleared T2Dx® Instrument
Launches the T2SARS-CoV-2™ Panel under FDA EUA Guidelines Launches the T2SARS-CoV-2™ Panel under FDA EUA Guidelines
LEXINGTON, Mass., June 26, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens, announced today that it issued inducement a...
Is (TTOO) Outperforming Other Medical Stocks This Year?
LEXINGTON, Mass., June 17, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that on June 16, 2020 it r...
Three new appointments add significant clinical and commercialization experience and expand board diversity Three new appointments add significant clinical and commercialization experience and...
Investors need to pay close attention to T2 Biosystems (TTOO) stock based on the movements in the options market lately.
Investors need to pay close attention to T2 Biosystems (TTOO) stock based on the movements in the options market lately.
Achievement Underscores the Clinical Value of Company’s Rapid Diagnostic Test for Sepsis-causing Bacterial Pathogens in Bloodstream Achievement Underscores the Clinical Value of Company’s Rapi...
T2 Biosystems, Inc. (TTOO) CEO John Sperzel on Q1 2020 Results - Earnings Call Transcript
T2 Biosystems' (TTOO) first-quarter performance is likely to reflect growth in product revenues.
LEXINGTON, Mass., April 15, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens, announced today that it issued inducement ...
New COVID-19 assay will be adapted to run on T2 Biosystems’ FDA-cleared T2Dx® Instrument New COVID-19 assay will be adapted to run on T2 Biosystems’ FDA-cleared T2Dx® Instrument
Suspends 2020 Financial Guidance Suspends 2020 Financial Guidance
Contract recognizes products that bring improvements to the health care industry Contract recognizes products that bring improvements to the health care industry
T2 Biosystems, Inc. (TTOO) CEO John Sperzel on Q4 2019 Results - Earnings Call Transcript
LEXINGTON, Mass., Jan. 17, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development and commercialization of innovative medical diagnostic products f...
LEXINGTON, Mass., Jan. 13, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development of innovative diagnostic products for critical unmet needs in healthcare, t...
Enters Exclusive Distribution Agreement to Expand Sales in Israel Enters Exclusive Distribution Agreement to Expand Sales in Israel
About TTOO
T2 Biosystems, an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. It provides T2 Magnetic Resonance technology that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument for detecting pathogens associated with sepsis and Lyme disease, and other applications, as we... [Read more...]
| Industry Diagnostics & Research | IPO Date Aug 7, 2014 |
| CEO John McDonough | Employees 118 |
| Stock Exchange NASDAQ | Ticker Symbol TTOO |
Financial Performance
In 2019, T2 Biosystems's revenue was $8.34 million, a decrease of -20.62% compared to the previous year's $10.50 million. Losses were -$59.01 million, 15.4% more than in 2018.
Analyst Forecasts
The average 12-month stock price forecast for T2 Biosystems is 3.22, which is an increase of 170.59% from the latest price.